Advertisement
New Zealand markets closed

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NZD/USD

    0.5962
    +0.0025 (+0.43%)
     

  • NZD/EUR

    0.5552
    +0.0006 (+0.11%)
     

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • OIL

    83.08
    +0.27 (+0.33%)
     

  • GOLD

    2,337.70
    -0.70 (-0.03%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,074.04
    +33.66 (+0.42%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,013.38
    -75.32 (-0.42%)
     

  • Hang Seng

    17,264.72
    +63.45 (+0.37%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • NZD/JPY

    92.7620
    +0.6470 (+0.70%)
     

2 Reasons This Beaten-Down Stock Could Be About to Rebound

Prosper Junior Bakiny, The Motley Fool
·4-min read
2 Reasons This Beaten-Down Stock Could Be About to Rebound

Gilead Sciences (NASDAQ: GILD) has kept its revenue and earnings growing in the past two years -- if ever so slightly -- largely thanks to Veklury, its COVID-19 therapy. Gilead Sciences' revenue rose by only about 1% year over year to $6.3 billion during the period. Excluding sales of Veklury, which dropped by 46% year over year to $445 million, Gilead Sciences' revenue for the quarter grew by a more impressive and respectable (by industry standards) 7%.

Continue reading